RNXT Valuation
RenovoRx Inc
$
1.240
- Overview
- Forecast
- Valuation
RNXT Relative Valuation
RNXT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNXT is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for RNXT's competitors is 41.99, providing a benchmark for relative valuation. RenovoRx Inc Corp (RNXT) exhibits a P/S ratio of 23.89, which is -43.12% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
WMT
Walmart Inc
97.985
USD
-0.26%
AVGO
Broadcom Inc
229.270
USD
+0.29%
NVDA
NVIDIA Corp
135.090
USD
-0.23%
ORCL
Oracle Corp
160.970
USD
+0.30%
TSLA
Tesla Inc
340.260
USD
-2.78%
XOM
Exxon Mobil Corp
106.225
USD
-1.82%
MSFT
Microsoft Corp
458.310
USD
+0.89%
META
Meta Platforms Inc
640.180
USD
-0.02%
AMZN
Amazon.com Inc
206.070
USD
+0.23%
AAPL
Apple Inc
208.310
USD
-1.40%
FAQ
Is RenovoRx Inc (RNXT) currently overvalued or undervalued?
RenovoRx Inc (RNXT) is now in the Fair zone, suggesting that its current forward PS ratio of 23.89 is considered Fairly compared with the five-year average of 0.99. The fair price of RenovoRx Inc (RNXT) is between to according to relative valuation methord.
What is RenovoRx Inc (RNXT) fair value?
How does RNXT's valuation metrics compare to the industry average?
What is the current P/B ratio for RenovoRx Inc (RNXT) as of May 19 2025?
What is the current FCF Yield for RenovoRx Inc (RNXT) as of May 19 2025?
What is the current Forward P/E ratio for RenovoRx Inc (RNXT) as of May 19 2025?